Your browser is no longer supported. Please, upgrade your browser.
OPTN OptiNose, Inc. daily Stock Chart
OPTN [NASD]
OptiNose, Inc.
Index- P/E- EPS (ttm)-2.56 Insider Own0.10% Shs Outstand45.91M Perf Week-36.12%
Market Cap194.59M Forward P/E- EPS next Y-1.31 Insider Trans40.86% Shs Float25.01M Perf Month-27.08%
Income-110.00M PEG- EPS next Q-0.56 Inst Own- Short Float26.43% Perf Quarter1.98%
Sales37.20M P/S5.23 EPS this Y2.00% Inst Trans-1.24% Short Ratio12.62 Perf Half Y-49.14%
Book/sh0.77 P/B5.35 EPS next Y39.40% ROA-66.40% Target Price- Perf Year-44.70%
Cash/sh3.14 P/C1.31 EPS next 5Y74.40% ROE-209.90% 52W Range3.28 - 11.66 Perf YTD-55.31%
Dividend- P/FCF- EPS past 5Y- ROI-75.50% 52W High-64.75% Beta-
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin84.10% 52W Low25.30% ATR0.78
Employees102 Current Ratio5.00 Sales Q/Q57.80% Oper. Margin- RSI (14)34.86 Volatility16.77% 12.82%
OptionableNo Debt/Eq2.98 EPS Q/Q10.20% Profit Margin- Rel Volume1.35 Prev Close4.12
ShortableYes LT Debt/Eq2.98 EarningsMay 07 AMC Payout- Avg Volume524.05K Price4.11
Recom1.80 SMA20-30.57% SMA50-19.69% SMA200-38.40% Volume181,795 Change-0.24%
Dec-18-19Initiated Cowen Outperform $25
Aug-08-18Initiated Cantor Fitzgerald Overweight
Jul-09-20 08:09AM  
Jul-05-20 03:05PM  
Jun-30-20 08:00AM  
Jun-22-20 08:30AM  
Jun-19-20 10:00AM  
May-27-20 04:30PM  
May-26-20 09:00AM  
May-14-20 04:15PM  
May-08-20 03:00PM  
May-07-20 04:01PM  
Apr-30-20 04:15PM  
Apr-29-20 08:47AM  
Apr-11-20 10:01AM  
Mar-16-20 09:15AM  
Mar-05-20 07:45AM  
06:30AM  
Feb-27-20 04:30PM  
Feb-26-20 12:30PM  
Feb-19-20 07:00AM  
Dec-17-19 07:03PM  
08:30AM  
Dec-10-19 12:12PM  
Nov-26-19 04:01PM  
Nov-21-19 09:00AM  
Nov-20-19 04:00PM  
Nov-17-19 08:00AM  
Nov-12-19 04:01PM  
Nov-07-19 06:02PM  
Nov-05-19 10:33AM  
Nov-01-19 08:00AM  
Oct-04-19 08:00AM  
08:00AM  
Sep-27-19 08:00AM  
Sep-26-19 08:15AM  
07:00AM  
Sep-17-19 04:01PM  
Sep-12-19 04:05PM  
Sep-11-19 01:34PM  
Aug-13-19 03:45PM  
Aug-12-19 10:23PM  
05:25PM  
04:02PM  
02:30PM  
Aug-05-19 10:30AM  
Aug-01-19 04:30PM  
Jul-11-19 12:13PM  
Jun-20-19 08:00AM  
Jun-19-19 04:30PM  
May-22-19 10:42AM  
May-09-19 11:23AM  
08:55AM  
07:46AM  
07:00AM  
May-02-19 10:33AM  
Apr-27-19 09:01AM  
Apr-25-19 07:00AM  
Mar-21-19 11:06AM  
Mar-06-19 12:22PM  
07:00AM  
Feb-27-19 07:00AM  
Feb-19-19 07:00AM  
Feb-15-19 07:00AM  
Feb-04-19 12:46PM  
07:00AM  
Dec-25-18 10:28AM  
Dec-13-18 07:56AM  
Dec-11-18 07:50AM  
07:00AM  
Dec-10-18 07:00AM  
Dec-05-18 04:30PM  
Nov-26-18 05:29PM  
Nov-13-18 10:15AM  
09:11AM  
07:00AM  
Oct-31-18 04:30PM  
Oct-22-18 08:10AM  
Oct-03-18 07:00AM  
Sep-24-18 04:30PM  
Aug-14-18 08:28PM  
12:48PM  
12:40PM  
07:26AM  
07:00AM  
06:00AM  
Aug-07-18 05:00PM  
Jul-02-18 05:11PM  
Jun-21-18 04:30PM  
Jun-20-18 09:39AM  
Jun-19-18 07:07PM  
07:00PM  
Jun-15-18 02:05PM  
Jun-12-18 12:10PM  
Jun-11-18 04:25PM  
Jun-07-18 01:16PM  
Jun-06-18 08:21PM  
Jun-04-18 04:56PM  
May-23-18 07:40AM  
May-14-18 08:35AM  
07:15AM  
07:00AM  
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Neil Robert PDirectorMar 09Buy5.325,00026,5967,000Mar 09 04:33 PM
Scodari Joseph CDirectorMar 06Buy5.708,70049,60521,230Mar 09 07:07 AM
Scodari Joseph CDirectorDec 06Buy8.226,10050,14212,530Dec 09 02:42 PM
Avista Capital Partners II GP,10% OwnerNov 25Sale9.171,250,00011,456,250807,995Nov 26 05:41 PM
Venkataraman SriramDirectorNov 25Sale9.171,250,00011,456,250807,995Nov 26 05:36 PM